Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Cardiology Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Cardiology Other
    Distinguishing Mutations From Rare Variants Key to Interpreting Genetic Testing in LQTS - (DGNews)
    Small Increases In Phosphorus May Mean Higher Risk of Heart Disease - (DGNews)
    A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease - (N Engl J Med)
    ACC Revises Guidelines for Perioperative Use of Beta Blockers - (DGNews)
    Effect of tailored practice and patient care plans on secondary prevention of heart disease in general practice: cluster randomised controlled trial - (BMJ)

    News archive

     Recent webcasts/CME - Cardiology Other
      Comorbidity in Patients with Rheumatoid Arthritis: What are the Real Concerns?
      Sleep Apnea and the Importance of Patient Screening
      Patient-Centered Approaches to the Evaluation and Management of Atrial Fibrillation
      Current Concepts and Management Strategies in Atrial Flutter
      Cancer, Liver, Infections, Cardiovascular Disease, and other Biologic Agents

      Webcasts/CME archive

       Recent cases - Cardiology Other
        Multiorgan Paradoxical Embolism Consequent to Acute Pulmonary Thromboembolism with Patent Foramen Ovale: A Case Report
        A Long-Term Follow-Up of a Girl With Dilated Cardiomyopathy After Mitral Valve Replacement and Septal Anterior Ventricular Exclusion
        Cardiac Injuries in Blunt Chest Trauma
        Nonsurgical Management of a Tricuspid Valvular Pedunculated Papillary Fibroelastoma
        Atypical Atrial Myxomas in Two Asymptomatic Patients: A Case Report

        Cases archive
          




        my personal edition > cardiology other > news
        divider

          E-Mail this DGNews to a colleague

        DGNews


        Viagra Prevents Anti-Cancer Drug Induced Heart Damage

        Circulation article describes Viagra's ability to stabilize

        RICHMOND, VA -- April 5, 2005 -- The popular impotence drug Viagra prevents damage to the heart from a potent chemotherapeutic agent frequently used in the treatment of breast cancer, leukemia and sarcomas, Virginia Commonwealth University researchers report.

        In the April 5 issue of Circulation: Journal of the American Heart Association, researchers demonstrated for the first time that administration of clinically relevant doses of Viagra, generically known as sildenafil citrate, one-hour prior to the administration of the anti-cancer drug doxorubicin (DOX) prevented heart damage at the cellular level. The research also showed that the impotence drug also prevented dilated cardiomyopathy and heart failure in a chronic mouse model. Furthermore, researchers observed a reduction of DOX-induced cell death, an improvement of heart function, and a reduction of electrophysiological abnormalities associated with heart sickness.

        "Our research holds promise for the potential use of sildenafil in patients receiving DOX as part of their chemotherapeutic regimen with the goal of reducing the incidence of DOX cardiomyopathy," said the lead author of the study, Rakesh C. Kukreja, PhD, professor of medicine, physiology and biochemistry at VCU.

        "Viagra stabilizes the mitochondria and protects against free-radical damage of the mitochondria and heart dysfunction caused by treatment with DOX by opening the mitochondrial KATP channels in cardiac cells," said Dr. Kukreja.

        Mitochondria are cellular organelles critical for converting oxygen into ATP, the key fuel for cellular function. According to Dr. Kukreja, free radicals generated in the mitochondria of cardiac cells by DOX lead to the break down of regular cellular function, resulting in programmed cardiac cell death. Over time, cell death has been linked to decreased heart function or heart failure.

        DOX is an effective chemotherapeutic agent commonly used in the treatment of many blood and solid tumor malignancies. Despite DOX's clinical efficacy for treatment of cancer, its use is associated with a delayed and progressive cardiomyopathy, often presenting several years after treatment cessation.

        "Viagra is able to protect the heart from damage that would otherwise disrupt normal cellular functioning," he said.

        Dr. Kukreja and his colleagues began studying sildenafil in 2002 as part of ongoing research into "preconditioning," a way to protect the heart muscle from serious damage in the future by subjecting it to very brief periods of deprivation of blood flow and, therefore, oxygen. In papers published in the September 2002 issue of the American Journal of Physiology and the March 2003 issue of Circulation Research, Kukreja and his colleagues observed a powerful, protective effect of Viagra in the heart during experimental heart attacks in animal models.

        The research was supported by a grant from the National Institutes of Health.


        SOURCE: Virginia Commonwealth University



        E-Mail this DGNews to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send